MedTrace Logo

Level of Expression and Prognostic Value of CXCL4, CXCL4L1 and CXCR3 in Renal Cell Carcinoma

NCT01339975 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 310

Last updated 2019-08-05

No results posted yet for this study

Summary

Despite novel treatment options, Renal Cell Carcinoma (RCC) has been characterized by a constant increase in its mortality and consequently requires an important involvement in translational research.

The aim of this study is to evaluate the interest of CXCL4, CXCL4L1 and CXCR3 as biomarkers in localized, locally advanced or metastatic RCC. Indeed these chemokines have shown anti-angiogenic and anti-tumor properties in experimental models and may be particularly interesting for prognostic and predictive purposes.

Conditions

  • Carcinoma
  • Carcinoma Renal Cell
  • Kidney Neoplasms
  • Kidney Diseases
  • Chemokines

Interventions

BIOLOGICAL

Biological sample

2 blood samples of 10mL + one urine sample * on pre-operative d-1/d, post-operative d1 and d5(+/-2), * one month post-operative, * at the end of the study in the absence of disease progression or at the date of recurrence or progression if the case arises.

BIOLOGICAL

Biological sample

2 blood samples of 10mL + one urine sample * before starting the therapy * at first therapeutic evaluation (2 or 3 months depending on the treatment chosen) * at the end of the study or at the date of disease progression.

Sponsors & Collaborators

  • University Hospital, Bordeaux

    lead OTHER

Principal Investigators

  • Jean-Christophe BERNHARD, Dr · University Hospital Bordeaux, France

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-06-06
Primary Completion
2014-05-31
Completion
2019-05-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01339975 on ClinicalTrials.gov